Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.81), $0.45 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $87 million versus the consensus estimate of $85.03 million.

GUIDANCE:

Ultragenyx Pharma reaffirms FY2021 revenue of $180-190 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.